Amphastar Pipeline Targets $10.5bn Market With Seven Generics
Company Performs Well On The Back Of Recently Launched Glucagon Rival
Amphastar announces that it has seven generic and three biosimilar products in development in order to target bigger markets. The company revealed that its insulin program is also developing towards interchangeable status.
